Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nodality Announces Publication of Promising Data in Melanoma in JTM

Published: Friday, May 30, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Nodality's SCNP platform holds strong potential in aiding the development of new cancer and immuno-oncology treatments.

Nodality, Inc. has announced promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Nodality's SCNP technology reveals functional biology underlying the most important and intractable diseases, providing critical insights to help guide the discovery and development of next-generation therapeutic agents.

According to data published in the current issue of the Journal of Translational Medicine (JTM), Nodality's researchers have identified key biomarkers in the blood that can help predict responses to new therapies for melanoma, including cancer immunotherapeutics.

“While there has been exciting recent progress in the treatment of melanoma, new therapies have been found to benefit only a subset of patients and are often associated with significant adverse effects,” commented Laura Brege, Nodality's President and Chief Executive Officer.

Brege continued, “With our highly sensitive and reproducible SCNP platform, we are able to attain a deep, functional understanding of how the immune system behaves in the presence of tumor cells and how cancer cells vary in their response to approved and promising development-stage therapies. In light of SCNP's broad range of capabilities and potential applications, we believe our technology can play an essential role in advancing pipelines of targets and therapeutics to deliver the next generation of drugs for cancer and other major illnesses.”

For access to the JTM article, titled “Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification,” please visit http://www.translational-medicine.com/content/12/S1/O13.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Protein-Based “Cancer Signature” Uncovered
Researchers investigated the expression of ribosomal proteins in human tissues and discovered a cancer type specific signature which could be used to predict the progression of the disease.
Ribosome Recycling as a Drug Target
Researchers explain mechanism that recycles bacterial ribosomes stalled on messenger RNAs that lack termination codons.
Predicting Leukaemia Development in Cancer Patients
Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia.
Survey of New York City Soil Uncovers Medicine-Making Microbes
Microbes have long been an invaluable source of new drugs. And to find more, we may have to look no further than the ground beneath our feet.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Cancer Signaling Pathway Illuminating Way To Therapy
Researchers refine a pro-growth signalling pathway, common to cancers, that can kill cancer cells while leaving healthy cells unharmed.
Breast Cancer Cells Starve for Cystine
Depriving triple negative breast cancer, a treatment-resistant form of breast cancer, of cystine results in cancer cell death.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!